Partnerships & Collaborations
At Silence we are developing novel RNAi based therapies with the potential to transform patients’ lives. We use our proprietary technology platform to advance the next generation of genetic medicines, designed to intervene at the root of the problem by targeting the expression of disease-causing genes.
We envisage partnerships with pharmaceutical and biotech companies, as well as leading academic institutions, as an essential component of our product development strategy. We are flexible and committed to creating collaborations that maximise value for each of the partners.
We welcome opportunities to discuss:
- Licensing of Silence proprietary technologies
- Licensing or co-development of Silence candidate products
- Collaborative projects (technology co-development or disease-area focused)
- Novel target genes